Heavy! Global mRNA Pharmaceutical Panorama.

Wen . . . Northwest, Wang do not stay from "no one asked" to "Mentingru City", after 20 years of development, mRNA technology gradually lifted the veil of mystery, mRNA drugs have become a new darling in the field of biopharmaceuticals, but also become the major pharmaceutical companies actively layout of the important track.
will take stock of mRNA drug companies, transactions and technologies and patents at home and abroad.
2000, CureVacCureVac AG was founded as the first company to successfully apply mRNA to the medical field.
RNA technologies used by CureVac include RNActive®, RNAntigen®, RNArt®, RNAdjuvant® and RN Antibody ®.
CureVac is the first but still uniposed company in the "mRNA Big Three" (mRNA Big Three, which refers to Moderna, BioNTech and CureVac), and cureVac plans to go to the U.S. for an IPO in June 2020, according to foreign media;
, CureVac has partnered with companies such as BI, Lilly and Sanofi.
2011, CureVac established an extensive partnership with Sanofi Pasteur, and in 2014, the two sides decided to further strengthen their partnership in the field of mRNA vaccines, which Sanofi will develop a cureVac-based RNActive vaccine.
2013, CureVac teamed up with Johnson and Johnson's Janssen Pharmaceuticals to develop a mRNA flu vaccine.
2014, CureVac partnered with Blinger Ingehan (BI) to conduct a clinical trial of CureVac's therapeutic mRNA lung cancer vaccine.
October 2017, CureVac partnered strategically with Lilly to develop and commercialize five cancer vaccine products for CureVac, and in November of the same year, CureVac partnered with CRISPR to develop Cas9 mRNA for in vivo gene editing.
2018, CureVac and Arcturus have established a strategic partnership to jointly identify, develop and commercialize new mRNA therapies.
2019, CureVac has a research partnership and licensing agreement with Genmab that combines CureVacmRNA technology and know-how with Genmab's proprietary antibody technology and expertise to focus on mRNA antibody product development.
July 2020, CureVac and GSK reached an 850 million euro strategic partnership on mRNA technology, which will be used to conduct research on infectious disease mRNA vaccines and monoclonal antibodies.
addition, CureVac has partnered with Auitas to obtain Acuitas' LNP technology.
CureVac has a total of 10 mRNAs in its research and development pipeline, led by the use of RNActive® technology immunotherapy for prostate cancer and non-small cell lung cancer, and an infectious disease mRNA prevention vaccine is also being developed.
among them, tumor vaccine CV8102 for melanoma and other adaptations, tumor vaccine CV9202 for non-small cell lung cancer adaptation, rabies preventive vaccine CV7202 and mRNA new crown vaccine have entered clinical I.
1 CureVac Product Pipeline, from: CureVac's official website, BioNTechBioNTech AG was founded in 2008 to develop more accurate and personalized immunotherapy.
based on its unique mRNA innovations, BioNTech builds three technology platforms for tumor immunity, preventive vaccines and protein substitution, and is also committed to the combination of CAR-T and TCR-T and mRNA applications, dual-specific antibodies and nanotechnology developed based on protein therapy platforms, and new checkpoint immunomodants, small molecule drugs, and diagnostic-related products.
, one of the "mRNA Big Three", has grown rapidly, listing on NASDAQ in 2019 and entering into strategic partnerships with a number of biopharmaceutical giants and biotech companies, including Pfizer, Sanofi, Lilly and Genentech.
On May 11, 2015, BioNTech entered into a partnership agreement with Lilly to develop new tumor immunotherapy treatments such as TCR for a total of more than $360 million; Based on BioNTech's mRNA research and development platform to discover and develop several mRNA tumor immunotherapy treatments worth up to $1.5 billion, BioNTech announced in 2019 that it would extend its research collaboration with Sanofi for November 2015, with Sanofi investing 80 million euros in BioNTech to jointly develop and commercialize mRNA-based cancer immunological drugs for solid tumors.
In 2016, BioNTech partnered with Bayer to develop a new generation of mRNA vaccines and drugs for animal health, and in September of the same year, BioNTech partnered with Roche's Genentech to develop an individualized mRNA tumor vaccine with a specific new etony.
In July 2018, BioNTech and Genevant announced that they would partner in the development of five mRNA treatment options for the treatment of rare diseases with high medical needs, and reached a series of exclusive licenses to apply Genevant's delivery technology to five oncology projects at BioNTech;
2020, BioNTech and Pfizer have partnered to develop a new mRNA vaccine, which is currently in Phase I clinical trials in Germany and the United States, and the new crown mRNA vaccine approved by BioNTech has been approved for clinical trials in China.
BioNTech's clinical pipeline focuses on tumor products, with the personalized mRNA tumor vaccine iNeST (BNT122), developed in cooperation with Genentech, making the fastest progress, melanoma adaptation entering phase II clinical phase, and multiple myeloma adaptation entering Phase I clinical phase.
bioNTech has conducted a total of 1 clinical Phase II study and 11 Clinical Phase I studies.
Figure 2 BioNTech Product Pipeline, from bioNTech's official website, (3) ModernaModerna Therapeutics, founded in 2010 to develop mRNA therapies, is the last of the "mRNA Big Three" to be established, but is valued well ahead of the other two companies.
Nasdaq in 2018, setting a record for the largest biotech IPO in history, valued at about $7.6 billion.
Most of Modena's partners are pharmaceutical giants, and in 2013, Moderna teamed up with AstraZeneca, which will give Moderna priority over targeting on oncology and cardiovascular disease.
In 2015, Moderna and Mercerton partnered on an infectious disease mRNA vaccine, which will give Mercerton commercialization of five of Modena's candidate products, in 2016, Moderna and Mercerton again partnered to provide new ideas for cancer based on mRNA-based personalized vaccine technology, and in 2018, Moderna and Mercerton developed mRNA vaccine mRNA-5671 for KRAS.
2016, Moderna signed a $300 million research and development licensing agreement with Vertex to treat cystic fibrosis with individualized mRNA therapy.
Moderna has 23 mRNA drug product lines, including 9 preventive vaccines, 4 system secretion and cell surface therapy, 2 cancer vaccines, 3 intra-tumor injection products, 1 local regenerative therapy, and 4 systemic intracellular therapies.
A total of 15 projects are currently in clinical development, of which mRNA-1647, mRNA-4157 and AZD8601 are the fastest-growing, targeting cytocytovirus (CMV) infections, tumors and heart failure and heart attacks, all of which have entered Phase II clinical phases.
Figure 3 Moderna Product Pipeline, from: Moderna's official website, (4) eTheRNAeTheRNA Immunotherapies was founded in 2013 by a Belgian biotechnology company, founded by Professor Kris Thielemans, a renowned immunologist at the Free University of Brussels, in partnership with other partners to develop immunotherapy for cancer and infectious diseases based on its proprietary mRNA TriMix platform.
TriMix technology for eTheRNA consists of three mRNA fragments expressed in caTLR4, CD40L, and CD70.
currently its product pipeline for melanoma has been carried out to phase II clinical stage, for breast cancer products have also entered phase I clinical.
TheRNA received a round of A financing of EUR 24 million in 2016 and a round of financing of EUR B of EUR 34 million in 2020.
In June 2020, eTheRNA will establish a strategic partnership with The Great Group, which will make a 9 million euro equity investment in eTheRNA once the relevant conditions agreed in the investment agreement are met, and the Group will receive approximately 13% of eTheRNA's Class B preferred shares and a director's seat when the equity investment is fully completed.
(5) Translate BioTranslate Bio was founded in 2011 as a mRNA treatment company dedicated to converting mRNA into therapeutic drugs.
Translate Bio, headquartered in Massachusetts, USA, was registered in November 2016 under the name RaNA Therapeutics and changed its name to Translate Bio in June 2017, using a proprietary MRTTM platform (originally developed by Shire and acquired by Translate Bio in 2016) to develop candidates for mRNA therapy.
In 2018, Translate Bio was listed on NASDAQ, the same year That Translate Bio partnered with Sanofi to develop mRNA vaccines for multiple infectious diseases using breakthrough mRNA platform technology, and in March 2020, the two sides continued to work together to develop mRNA vaccines for new coronary virus pneumonia.
but from the pipeline, Translate Bio's main product layout is still mainly therapeutic products, of which the treatment of cystic fibrosis product MRT5005 is the fastest progress, has entered the clinical stage.
4 Translate Bio Product Pipeline, from the official website of Translate Bio, (6) EthrisEthris was founded in 2009 as a mRNA treatment development company focused on respiratory diseases.
Ethris uses its pioneering SNIM ® RNA technology platform to direct mRNA into the lesions site.
currently, all Ethris pipeline products are in the preclinical stage, with ETH42 making the fastest progression for the treatment of primary cilia dyskinesia (PCD).
In 2017, Ethris and AstraZenefa reached a five-year partnership for mRNA research, and AstraZenephone's MedImmune and Innovative Medicines (IMED) units will be granted exclusive rights to SNAP®RNA technology to develop respiratory drug products for the treatment of asthma, chronically retarded lungs and endeminal pulmonary fibrosis.
5 Ethris Product Pipeline, from: Ethris's official website, (7) Argos Argos Therapeutics was founded in 1997 by Nobel Laureate Ralph Steinman, whose core technology platform, Arcelis® Accurate immunotherapy techniques that use mRNA isolated from a patient's tumor to gene-edit the patient's antigen delivery cells so that the antigen-presenting cells produce tumor-specific antibodies to activate the body's immune response to tumors and are suitable for the treatment of a variety of cancers and infectious diseases.
Argos had planned to list on NASDAQ as early as 2012, but announced its withdrawal from the IPO in March due to market conditions and other reasons until it was listed on NASDAQ in 2014.
April 2015, Argos entered into a licensing agreement with Leme (Hong Kong) Co., Ltd. to acquire the right to produce, develop and commercialize AGS-003 in Chinese mainland, Hong Kong, Taiwan and Macau.
But the unexpected, in 2017, Leme Pharmaceuticals issued an announcement that the impairment of its collective assets of Argos shares led to a sharp decline in the company's performance, leading to Argos heavy in research products AGS-003 effect is not optimistic, and then Argos share price plummeted.
In April 2018, Argos listed on the NASDAQ OTCQB, an over-the-over-the-board exchange, but its share price remained unstoward; in August, Argos shut down Phase II clinical trials of AGS-004, another HIV immunotherapy candidate; and in November, Argos filed for bankruptcy.
, the drug AGS-003, a candidate drug for the treatment of metastatic renal cell carcinoma (mRCC), is still in Phase 3 clinical trials, according to Argos's website.
Argos had expected the product to complete Phase III clinical studies by mid-2016, 201, in accordance with the Clinical Trials Program.